IgG N-Glycosylation During Atorvastatin Therapy After Acute Coronary Syndrome is Associated with LDL Cholesterol Reduction
Journal of Clinical Medicine · 16.04.2026 · 15 (8) · 3056
DOI: 10.3390/jcm15083056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.04.2026. Verfasst von Domagoj Mišković und 7 weiteren Autor:innen. Beteiligte Einrichtung: General Hospital "Dr. Josip Benčević" Slavonski Brod, 35000 Slavonski Brod, Croatia. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objective: Immunoglobulin G (IgG) N-glycosylation is an important regulator of immune function and systemic inflammation and has been associated with cardiometabolic diseases. However, little is known about how IgG glycosylation changes during the course of acute coronary syndrome (ACS) and whether these alterations relate to lipid-lowering response after the initiation of statin therapy. The primary aim of this study was to investigate IgG N-glycosylation following ACS and evaluate its association with response to atorvastatin therapy defined as baseline LDL cholesterol reduction of ≥50%.
Methods
In this prospective cohort study, 79 statin-naïve patients hospitalized for the first episode of ACS and treated with atorvastatin 80 mg daily after percutaneous coronary intervention were followed longitudinally. Plasma samples were collected at admission (acute phase), discharge (subacute phase), and follow-up (chronic phase). A control group of 21 individuals received atorvastatin for primary prevention. IgG was isolated from plasma, and N-glycans were released, fluorescently labeled with 2-aminobenzamide, and analyzed using hydrophilic interaction-based ultra-high-performance liquid chromatography with fluorescence detection. Derived glycan traits were calculated, including agalactosylated (G0), monogalactosylated (G1), digalactosylated (G2), core fucosylated (F), bisected (B), and sialylated (S) glycans.
Results
No significant differences in derived IgG glycan traits were observed between ACS patients and controls at baseline or follow-up. Within the ACS group, a longitudinal analysis revealed significant increases in G0 and F and a decrease in G2 between the acute and chronic phases. A total of 65% of patients achieved ≥50% reduction in LDL cholesterol (LDL-C), whereas only 22% reached the guideline-recommended LDL-C target of 3.9 mmol/L, those who failed to achieve ≥50% LDL-C reduction had significantly lower G0 and higher S across all time points.
Conclusions
Specific glycan traits are associated with the degree of LDL-C reduction achieved during statin therapy, particularly in patients with high baseline LDL-C. These findings suggest that IgG glycosylation patterns may reflect biological phenotypes associated with differential lipid-lowering responsiveness after ACS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- General Hospital "Dr. Josip Benčević" Slavonski Brod, 35000 Slavonski Brod, Croatia.
- Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
- Genos Glycoscience Research Laboratory, 10000 Zagreb, Croatia.
- Clinic for Cardiovascular Medicine, Dubrava University Hospital, 10000 Zagreb, Croatia.
- University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
- School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
ORCID-Profile: Domagoj Mišković, Nikol Mraz, Barbara Radovani Trbojević, Ivana Jurin, Ivan Gudelj, Irzal Hadžibegović
Zitieren
APA
Mišković, D., Mraz, N., Radovani Trbojević, B., Jurin, I., Đanić Hadžibegović, A., Gudelj, I., Lauc, G., & Hadžibegović, I. (2026). IgG N-Glycosylation During Atorvastatin Therapy After Acute Coronary Syndrome is Associated with LDL Cholesterol Reduction. Journal of Clinical Medicine, 15(8), 3056. https://doi.org/10.3390/jcm15083056
Vancouver
Mišković D, Mraz N, Radovani Trbojević B, Jurin I, Đanić Hadžibegović A, Gudelj I, et al. IgG N-Glycosylation During Atorvastatin Therapy After Acute Coronary Syndrome is Associated with LDL Cholesterol Reduction. Journal of Clinical Medicine. 2026;15(8):3056. doi:10.3390/jcm15083056
BibTeX
@article{Mikovi2026,
author = {Mišković, Domagoj and Mraz, Nikol and Radovani Trbojević, Barbara and Jurin, Ivana and Đanić Hadžibegović, Ana and Gudelj, Ivan and Lauc, Gordan and Hadžibegović, Irzal},
title = {IgG N-Glycosylation During Atorvastatin Therapy After Acute Coronary Syndrome is Associated with LDL Cholesterol Reduction},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {8},
pages = {3056},
doi = {10.3390/jcm15083056}
}
EUVIMED